First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine

• Walsh SR,
• Seaman MS,
• Johnson JA,
• Tucker RP,
• Krause KH,
• Weijtens M,
• Pau MG,
• Goudsmit J,
• Dolin R,
• Barouch DH,
• Baden LR

Affiliations

Walsh SR

Seaman MS

Johnson JA

Tucker RP

Krause KH

Weijtens M

Pau MG

Goudsmit J

Dolin R

Barouch DH

Baden LR